Brookfield Corp’s Myriad Genetics MYGN Stock Holding History

Brookfield Corp’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-27,627	Closed	-$696K	–	703
2022 Q1	$696K	Buy	+27,627	New	+$707K	﹤0.01%	532
2021 Q2	–	Sell	-11,438	Closed	-$348K	–	612
2021 Q1	$348K	Sell	11,438 -5,430	-32%	-$154K	﹤0.01%	433
2020 Q4	$334K	Buy	+16,868	New	+$272K	﹤0.01%	417

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Brookfield Corp's MYGN Position: Q2 2022 in Review

Brookfield Corp sold out of Myriad Genetics (MYGN) in Q2 2022, closing a stake of 27,627 shares — an estimated $696K sold.

Brookfield Corp first reported a position in MYGN in Q4 2020 and held it in 3 quarters. The position peaked at $696K in Q1 2022. 198 funds tracked by Wall St. Rank hold MYGN as of Q2 2022.

Brookfield Corp reported no remaining Myriad Genetics position as of Q2 2022 after selling out during the quarter.
Brookfield Corp sold 27,627 Myriad Genetics shares in Q2 2022, an estimated $696K.
Brookfield Corp first reported a position in Myriad Genetics in Q4 2020 and held it in 3 quarters.
Brookfield Corp's Myriad Genetics position peaked at $696K in Q1 2022.
198 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2022.

Based on Brookfield Corp's 13F filing for Q2 2022, filed 15 Aug 2022.